{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:35:08Z","timestamp":1792028108754,"version":"4.4.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.jaci.2019.03.017","type":"journal-article","created":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T09:04:33Z","timestamp":1556874273000},"page":"1676-1687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":139,"title":["PI3K pathway defects leading to immunodeficiency and immune dysregulation"],"prefix":"10.1016","volume":"143","author":[{"given":"Cristiane J.","family":"Nunes-Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbu","family":"Uzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio D.","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2019.03.017_bib1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2019.03.017_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaci.2019.03.017_bib4","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.jaci.2019.03.017_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib6","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous\u00a0splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2019.03.017_bib7","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1172\/JCI75746","article-title":"A\u00a0human immunodeficiency caused by mutations in the PIK3R1 gene","volume":"124","author":"Deau","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2019.03.017_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.20112533","article-title":"Agammaglobulinemia and absent B lineage cells in a patient lacking the p85\u03b1 subunit of PI3K","volume":"209","author":"Conley","year":"2012","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2019.03.017_bib9","first-page":"671","article-title":"Identification of a phosphoinositide 3-kinase delta (PI-3K) P110delta (PI3KCD) deficient individual","volume":"33","author":"Zhang","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase delta syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fimmu.2018.00543","article-title":"Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase \u03b4 syndrome: the European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase \u03b4 Syndrome Registry","volume":"9","author":"Maccari","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3389\/fimmu.2017.02005","article-title":"Epstein-Barr virus susceptibility in activated PI3K\u03b4 syndrome (APDS) immunodeficiency","volume":"8","author":"Carpier","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","article-title":"Signaling by the phosphoinositide 3-kinase family in immune cells","volume":"31","author":"Okkenhaug","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00109-015-1352-5","article-title":"Molecules in medicine mini-review: isoforms of PI3K in biology and disease","volume":"94","author":"Vanhaesebroeck","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.jaci.2019.03.017_bib17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","article-title":"Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility","volume":"34","author":"Crank","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib18","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jaci.2016.03.055","article-title":"Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase delta syndrome-like immunodeficiency","volume":"138","author":"Tsujita","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib19","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2016.08.028","article-title":"Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD","volume":"139","author":"Dulau Florea","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clim.2017.01.004","article-title":"Genetic defects in PI3K\u03b4 affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections","volume":"176","author":"Wentink","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.clim.2015.04.014","article-title":"Altered germinal center reaction and abnormal B cell peripheral maturation in PI3KR1-mutated patients presenting with HIGM-like phenotype","volume":"159","author":"Lougaris","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.clim.2015.10.008","article-title":"De\u00a0novo PIK3R1 gain-of-function with recurrent sinopulmonary infections, long-lasting chronic CMV-lymphadenitis and microcephaly","volume":"162","author":"Kuhlen","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clim.2017.03.004","article-title":"Mutations in PIK3R1 can lead to APDS2, SHORT syndrome or a combination of the two","volume":"179","author":"Bravo Garcia-Morato","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-0043-104218","article-title":"Variant PIK3R1 hypermorphic mutation and clinical phenotypes in a family with short statures, mild immunodeficiency and lymphoma","volume":"229","author":"Hauck","year":"2017","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.jaci.2019.03.017_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.clim.2016.09.011","article-title":"Gain-of-function mutation in PIK3R1 in a patient with a narrow clinical phenotype of respiratory infections","volume":"173","author":"Martinez-Saavedra","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib26","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/pai.12585","article-title":"Activated PI3Kdelta syndrome type 2: two patients, a novel mutation, and review of the literature","volume":"27","author":"Olbrich","year":"2016","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s10875-016-0281-6","article-title":"Dominant splice site mutations in PIK3R1 cause hyper IgM Syndrome, Lymphadenopathy and Short Stature","volume":"36","author":"Petrovski","year":"2016","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib28","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1073\/pnas.1617244114","article-title":"Conformational disruption of PI3K\u03b4 regulation by immunodeficiency mutations in PIK3CD and PIK3R1","volume":"114","author":"Dornan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaci.2019.03.017_bib29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tranon.2018.11.003","article-title":"PTEN hamartoma tumor syndrome and immune dysregulation","volume":"12","author":"Eissing","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1016\/j.jaci.2019.03.017_bib30","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2015-103266","article-title":"Cowden's syndrome with immunodeficiency","volume":"52","author":"Browning","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.jaci.2019.03.017_bib31","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.jaci.2016.07.010","article-title":"Increased PI3K\/Akt activity and deregulated humoral immune response in human PTEN deficiency","volume":"138","author":"Driessen","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib32","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2018.04.032","article-title":"Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase \u03b4 syndrome type 1","volume":"143","author":"Okano","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib33","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13229-017-0182-4","article-title":"Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and\/or autism","volume":"8","author":"Yeung","year":"2017","journal-title":"Mol Autism"},{"key":"10.1016\/j.jaci.2019.03.017_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1053\/j.gastro.2012.01.011","article-title":"Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome","volume":"142","author":"Heindl","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2019.03.017_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2016.03.059","article-title":"Immune dysregulation in patients with PTEN hamartoma tumor syndrome: analysis of FOXP3 regulatory T cells","volume":"139","author":"Chen","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10875-014-0109-1","article-title":"Gain of function mutations of PIK3CD as a cause of primary sclerosing cholangitis","volume":"35","author":"Hartman","year":"2015","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jaci.2018.04.030","article-title":"Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity","volume":"143","author":"Edwards","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib38","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fimmu.2018.00237","article-title":"Herpesviruses in the activated phosphatidylinositol-3-kinase-\u03b4 syndrome","volume":"9","author":"Cohen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib39","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jaci.2017.03.026","article-title":"Novel PIK3CD mutations affecting N-terminal residues of p110\u03b4 cause activated PI3K\u03b4 syndrome (APDS) in humans","volume":"140","author":"Takeda","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib40","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib41","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archotol.133.11.1157","article-title":"Airway obstruction caused by PTEN hamartoma (Bannayan-Riley-Ruvalcaba) syndrome","volume":"133","author":"Sharma","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaci.2019.03.017_bib42","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jaip.2018.01.005","article-title":"Liver disturbances in activated phosphoinositide 3-kinase \u03b4 syndrome","volume":"6","author":"Ben-Yakov","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2019.03.017_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/cei.12706","article-title":"Activating PI3Kdelta mutations in a cohort of 669 patients with primary immunodeficiency","volume":"183","author":"Elgizouli","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib44","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1093\/ecco-jcc\/jjx180.047","article-title":"Activating PIK3CD mutations cause severe intestinal lymphonodular hyperplasia and an IBD-like phenotype","volume":"12","author":"Farachi","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2019.03.017_bib45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jmg.2004.024646","article-title":"Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations","volume":"42","author":"Butler","year":"2005","journal-title":"J Med Genet"},{"key":"10.1016\/j.jaci.2019.03.017_bib46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ajhg.2013.06.005","article-title":"Mutations in PIK3R1 cause SHORT syndrome","volume":"93","author":"Dyment","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2019.03.017_bib47","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/cge.12263","article-title":"PIK3R1 mutations in SHORT syndrome","volume":"86","author":"Schroeder","year":"2014","journal-title":"Clin Genet"},{"key":"10.1016\/j.jaci.2019.03.017_bib48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fimmu.2018.00575","article-title":"Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in class IA phosphoinositide 3-kinases","volume":"9","author":"Dornan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib49","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajhg.2013.05.023","article-title":"SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling","volume":"93","author":"Chudasama","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2019.03.017_bib50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ajhg.2013.05.019","article-title":"PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy","volume":"93","author":"Thauvin-Robinet","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaci.2019.03.017_bib51","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1084\/jem.20180010","article-title":"Germline-activating mutations in PIK3CD compromise B cell development and function","volume":"215","author":"Avery","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2019.03.017_bib52","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1078\/0171-2985-00198","article-title":"Expansion of CD19(hi)CD21(lo\/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia","volume":"206","author":"Warnatz","year":"2002","journal-title":"Immunobiology"},{"key":"10.1016\/j.jaci.2019.03.017_bib53","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jaci.2017.11.042","article-title":"Mutations in PI3K110\u03b4 cause impaired natural killer cell function partially rescued by rapamycin treatment","volume":"142","author":"Ruiz-Garc\u00eda","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clim.2015.12.008","article-title":"The case of an APDS patient: Defects in maturation and function and decreased in\u00a0vitro anti-mycobacterial activity in the myeloid compartment","volume":"178","author":"Chiriaco","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10875-017-0393-7","article-title":"Persistent impairment of T-cell regeneration in a patient with activated PI3K delta syndrome","volume":"37","author":"Goto","year":"2017","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib56","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3389\/fimmu.2018.00568","article-title":"Enhanced AKT phosphorylation of circulating b cells in patients with activated PI3K\u03b4 syndrome","volume":"9","author":"Asano","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib57","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.3389\/fimmu.2018.02172","article-title":"Class-switch recombination (CSR)\/hyper-IgM (HIGM) syndromes and phosphoinositide 3-kinase (PI3K) defects","volume":"9","author":"Jhamnani","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib58","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41590-018-0182-3","article-title":"Hyperactivated PI3Kdelta promotes self and commensal reactivity at the expense of optimal humoral immunity","volume":"19","author":"Preite","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib59","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1084\/jem.20180617","article-title":"Activated PIK3CD drives innate B cell expansion yet limits B cell-intrinsic immune responses","volume":"215","author":"Wray-Dutra","year":"2018","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2019.03.017_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clim.2016.01.016","article-title":"Reduced germinal center follicular helper T cells but normal follicular regulatory T cells in the tonsils of a patient with a mutation in the PI3KR1 gene","volume":"164","author":"Di Fonte","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib61","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fimmu.2018.00338","article-title":"Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome","volume":"9","author":"Condliffe","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib62","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3389\/fimmu.2018.00966","article-title":"\u201cImmune TOR-opathies,\u201d a novel disease entity in clinical immunology","volume":"9","author":"Jung","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib63","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJMe1400055","article-title":"Idelalisib\u2014a PI3K\u03b4 inhibitor for B-cell cancers","volume":"370","author":"Fruman","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2019.03.017_bib64","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.jaci.2019.03.017_bib65","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1021\/acs.jmedchem.5b00767","article-title":"Optimization of novel indazoles as highly potent and selective inhibitors of phosphoinositide 3-kinase delta for the treatment of respiratory disease","volume":"58","author":"Down","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.jaci.2019.03.017_bib66","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d\u2014targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.03.017_bib67","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.clinthera.2018.06.011","article-title":"Safety, tolerability, and pharmacokinetics of single and repeat doses of nemiralisib administered via the ellipta dry powder inhaler to healthy subjects","volume":"40","author":"Wilson","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2019.03.017_bib68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/cpdd.614","article-title":"Evaluation of the safety, tolerability, and pharmacokinetics of GSK2269557 (nemiralisib) administered via dry powder inhaler to healthy Japanese subjects","volume":"8","author":"Ino","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jaci.2019.03.017_bib69","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/jpet.118.249516","article-title":"A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma","volume":"367","author":"Khindri","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaci.2019.03.017_bib70","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pupt.2017.08.008","article-title":"Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kdelta inhibitor under development for the treatment of COPD","volume":"46","author":"Cahn","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaci.2019.03.017_bib71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaci.2018.08.039","article-title":"Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase \u03b4 syndrome: who, when, and how?","volume":"143","author":"Notarangelo","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib72","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.jaci.2018.06.039","article-title":"Primary immunodeficiency disorder caused by phosphoinositide 3-kinase \u03b4 deficiency","volume":"142","author":"Sogkas","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib73","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jaci.2017.10.033","article-title":"Dual loss of p110\u03b4 PI3-kinase and SKAP (KNSTRN) expression leads to combined immunodeficiency and multisystem syndromic features","volume":"142","author":"Sharfe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib74","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10875-017-0462-y","article-title":"Autosomal recessive agammaglobulinemia due to a homozygous mutation in PIK3R1","volume":"38","author":"Tang","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib75","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jaci.2018.10.005","article-title":"Human primary immunodeficiency caused by expression of a kinase-dead p110\u03b4 mutant","volume":"143","author":"Cohen","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/jmedgenet-2016-104484","article-title":"A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children","volume":"54","author":"Hansen-Kiss","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.jaci.2019.03.017_bib77","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1385\/CRIAI:19:2:183","article-title":"X-linked agammaglobulinemia","volume":"19","author":"Conley","year":"2000","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib78","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10875-014-0056-x","article-title":"Autoimmunity and inflammation in X-linked agammaglobulinemia","volume":"34","author":"Hernandez-Trujillo","year":"2014","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib79","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.humpath.2015.05.011","article-title":"Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency\u2014histologic and immunohistochemical analyses of 16 cases","volume":"46","author":"Rao","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jaci.2019.03.017_bib80","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","article-title":"The treatment of activated PI3K\u03b4 syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib81","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.3389\/fimmu.2018.01758","article-title":"Genetic defects in phosphoinositide 3-kinase \u03b4 influence CD8","volume":"9","author":"Cannons","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib82","article-title":"Activated phosphoinositide 3 kinase delta syndrome (APDS): a primary immunodeficiency mimicking lymphoma","author":"Baleydier","year":"2018","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.jaci.2019.03.017_bib83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2019.03.017_bib84","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jaci.2019.03.017_bib85","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature21406","article-title":"Phosphatidylinositol 3-kinase \u03b4 blockade increases genomic instability in B cells","volume":"542","author":"Compagno","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2019.03.017_bib86","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1038\/s41467-018-05674-8","article-title":"PI3K\u03b4 hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner","volume":"9","author":"Stark","year":"2018","journal-title":"Nat Commun"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167491930421X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167491930421X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:16:57Z","timestamp":1758791817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167491930421X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S009167491930421X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2019.03.017","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PI3K pathway defects leading to immunodeficiency and immune dysregulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2019.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}